Rifalazil

利福拉齐

Report date: 2025/08/20 16:51:13
NME

Base Information

Drug NameRifalazil
Drug Alias NameRifalaziloRifalazilumABI-1648KRM-1648PA-1648 +[6] 
ClassificationSmall molecules > Heterocyclic drugs > Antibiotics
Mechanisms of ActionBacterial DNA-directed RNA polymerase inhibitors
TargetsBacterial DNA-directed RNA polymerase
Therapy Area/IndicationsPeripheral Vascular DiseasesIntermittent ClaudicationCoronary Artery Disease +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited StatesRussian Federation +[4] 
CombinationsNo
Global Highest StatusPending (Phase 3 Clinical)
Highest Status in ChinaN/A
Originator CompaniesKaneka Co
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesActivbiotics Pharma Llc
Active IndicationsN/A
Inactive IndicationsPeripheral Vascular DiseasesIntermittent ClaudicationCoronary Artery Disease +[5] 

Other Information

ATC CodeN/A
Related LinksWikipediaDrugBankKEGG